Abstract
Cell and gene therapy, offering unprecedented solutions for complex diseases, have attracted significant attention in both the scientific and financial communities. This article explores the tumultuous financial journey of companies specializing in these advanced thera-peutic modalities. The discussion illuminates the volatility of share prices, challenges in valuation, and complexities in fundraising while delving into the inherent risks of the cell and gene therapy development pathway. Through an examination of various strategies, the article underscores the importance of diverse investment sources, robust collaborations, risk-sharing models, and portfolio diversification in ensuring financial stability. As the field burgeons, un-derstanding these financial dynamics is paramount for stakeholders aiming to harness the transformative potential of cell and gene therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Applied Drug Research, Clinical Trials and Regulatory Affairs
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
